SECTION 1: PROPRIETARY BIOTECHNOLOGY PLATFORM

Engineering Bioactive Materials for Translational Impact

Engineering Bioactive Materials for Translational Impact

At LACTERA, our proprietary platform bridges laboratory molecular insight with industrial-scale bioprocessing. We target complex tissue healing pathways through precision fermentation bioengineering and skin microbiota modulation.

At LACTERA, our proprietary platform bridges laboratory molecular insight with industrial-scale bioprocessing. We target complex tissue healing pathways through precision fermentation bioengineering and skin microbiota modulation.

SECTION 2: CORE TECHNICAL ADVANTAGES

[01 / Microenvironment Modulation]: Dynamically balances the skin and tissue microbiome to accelerate optimal wound healing.

[02 / Precision Fermentation]: Utilizes state-of-the-art bioprocessing to synthesize high-purity bioactive materials from soy concentrates.

[03 / Scalable Bioprocesses]: Expertly bridges laboratory discovery with robust, consistent, and commercially viable large-scale manufacturing.

[04 / Multi-Pathway Regeneration]: Concurrently drives cell proliferation, extracellular matrix deposition, and targeted tissue closure.

[05 / Clinically Validated Safety]: Demonstrated exceptional biocompatibility and patient tolerance across multi-center randomized controlled trials.

SECTION 3: THERAPEUTIC PIPELINE & TARGET APPLICATIONS

01

[Diabetic Foot Ulcers (DFU)] — Targeted intervention for complex, chronic non-healing ulcers, successfully reducing average healing cycles from 165.9 to 89.6 days based on June 2026 British Journal of Dermatology data.

02

[Post-Surgical Healing & Regeneration] — Structural tissue repair and optimized remodeling post-reconstructive surgery to minimize scar tissue.

03

[Acute & Chronic Soft Tissue Wounds] — Broad-spectrum utility across traumatic wounds, deep tissue pressure sores, and complex venous stasis ulcers.